Press Releases April 30, 2026 07:30 AM

Yuanbao Inc. Files its Annual Report on Form 20-F for Fiscal Year 2025

Yuanbao Inc. files its FY 2025 annual report with the SEC, detailing operations as a tech-driven online insurance distributor.

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
YB

Yuanbao Inc., a Nasdaq-listed technology-driven online insurance distributor in China, announced the filing of its annual report on Form 20-F for fiscal year 2025 with the U.S. Securities and Exchange Commission. The report includes audited consolidated financial statements and is accessible via the company's investor relations website. Yuanbao serves over ten million consumers by providing customized insurance solutions throughout the insurance lifecycle using proprietary technology.

Yuanbao Inc. Files its Annual Report on Form 20-F for Fiscal Year 2025
YB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Yuanbao filed its annual report for fiscal year 2025 with the SEC, reaffirming transparency to investors.
  • The company operates as a technology-driven online insurance distributor in China, serving over ten million customers.
  • Yuanbao leverages advanced technology and data-driven insights to customize insurance solutions and enhance consumer engagement.

BEIJING, April 30, 2026 (GLOBE NEWSWIRE) -- Yuanbao Inc. (“Yuanbao” or the “Company”) (NASDAQ: YB), a leading technology-driven online insurance distributor in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (“SEC”) on April 30, 2026. The annual report can be accessed on the Company’s investor relations website at ir.yb-inc.com.

The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Investor Relations Department, Yuanbao Inc., Building 2, No.8 Beichen West Road, Chaoyang District, Beijing, 100101, the People’s Republic of China or via email at ir@yb-inc.com.

About Yuanbao Inc.

Yuanbao Inc. is a leading technology-driven online insurance distributor in China, committed to protecting health and well-being through innovative technology. Leveraging its proprietary consumer service cycle engine and advanced technologies, Yuanbao delivers customized insurance solutions from its partnered insurance carriers to over ten million insurance consumers throughout the entire insurance lifecycle, ranging from personalized recommendations to post-sales services. Through deep collaboration with insurance carriers and the use of data-driven insights, Yuanbao empowers carriers to tailor flagship products, enhances consumer engagement, and drives scalable and efficient distribution.

For more information, please visit: ir.yb-inc.com.

For investor and media inquiries, please contact:

In China:

Yuanbao Inc.
E-mail: ir@yb-inc.com

Piacente Financial Communications
Helen Wu
Tel: +86-10-6508-0677
E-mail: yb@thepiacentegroup.com

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
E-mail: yb@thepiacentegroup.com


Risks

  • Dependence on the Chinese insurance market, which may be subject to regulatory changes impacting Yuanbao's operations.
  • Competition in the online insurance distribution sector could affect market share and profitability.
  • Potential risks related to technology and data security inherent in Yuanbao's tech-driven business model.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026